Fireside Chat: Interrogating Next-Generation RNA Value Propositions to Define True Advantage Beyond Linear mRNA & Accelerate Clinical Adoption
- Clarify which benefits justify moving beyond linear mRNA, and how to differentiate next-gen RNA platforms to secure stakeholder buy-in
- Pinpoint structural reasons clinical translation has lagged expectations to avoid repeat failures and sharpen value propositions
- Define where circRNA or saRNA genuinely outperform existing modalities to strengthen investment cases and stand out in a crowded landscape